EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Perampanel as a second‐line therapy to midazolam reduces soman‐induced status epilepticus and neurodegeneration in rats

Hailey G Steier, Caroline R Schultz, Jerome Niquet iD, Donna A Nguyen, Michael F Stone, Abiel K Biney, Marcio de Araujo Furtado, Claude G Wasterlain iD, Lucille A Lumley

Epilepsia Open · 2025

DOI: 10.1002/epi4.70083 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia Open, 2025. Verfasst von Hailey G Steier und 8 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Department, U.S. Army Medical Research Institute of Chemical Defense (USAMRICD), Aberdeen Proving Ground, Maryland, USA. Hauptthemen laut MEDLINE: Status Epilepticus, Pyridones, Midazolam, Soman. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

A benzodiazepine (diazepam or midazolam) is one of the current standards of care therapies to effectively terminate organophosphorus nerve agent‐induced status epilepticus when administered shortly after onset. Preclinical studies showed that benzodiazepines were less effective in stopping status epilepticus when treatment was delayed up to 30 min from the time of organophosphorus exposure, highlighting the need for adjuncts to midazolam in a delayed treatment scenario. In this study, we evaluated the alpha‐amino‐3‐hydroxy‐5‐methylisoxazole‐4‐propionic acid (AMPA) receptor antagonist perampanel for efficacy as a second‐line antiseizure medication against soman‐induced benzodiazepine‐refractory status epilepticus.

Methods

Adult male Sprague–Dawley rats were exposed to a seizure‐inducing dose of soman and treated with midazolam (3 mg/kg; IP) 40 min after seizure onset, followed by perampanel (4 mg/kg; IP) or vehicle 20 min later. Electroencephalography (EEG) was recorded continuously for 2 weeks for analysis of seizure activity, after which brains were processed for an assessment of neurodegeneration.

Results

Compared to midazolam alone, perampanel administered 20 min after midazolam lowered the seizure duration during the first 24 h after soman exposure and reduced the EEG power integral over the 1 and 6 h period following treatment. Rats treated with perampanel as second‐line therapy to midazolam had reduced incidence and number of spontaneous recurrent seizures compared to those treated with midazolam alone. The perampanel treatment also reduced neurodegeneration in the fiber tracts, amygdala, and hippocampus. Significance The seizure‐protective effects of perampanel as second‐line therapy to midazolam provide support for perampanel in treating benzodiazepine‐refractory status epilepticus induced by exposure to organophosphorus nerve agents. Plain Language Summary Treatment of status epilepticus, a life‐threatening condition of prolonged seizures, becomes less effective when treatment is delayed. This study used a preclinical rat model of chemical‐induced seizure to evaluate the ability of the antiseizure medication perampanel as a second‐line therapy to midazolam in the treatment of status epilepticus. We show that perampanel following midazolam treatment improved seizure outcomes and reduced brain damage caused by status epilepticus, compared to midazolam alone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Status EpilepticusPyridonesMidazolamSomanAnticonvulsantsNeurodegenerative DiseasesAnimalsNitrilesMaleRats, Sprague-DawleyRatsElectroencephalographyDisease Models, Animal

Stichwörter der Autor:innen

AMPAantiseizure medicationcholinergicorganophosphorus nerve agentpharmacoresistance

Substanzen

perampanelNitrilesPyridonesMidazolamSomanAnticonvulsants

Autor:innen und Institutionen

  • Neuroscience Department, U.S. Army Medical Research Institute of Chemical Defense (USAMRICD), Aberdeen Proving Ground, Maryland, USA.
  • Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
  • Epilepsy Research Laboratory (151), Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA.
  • BioSEaD, LLC, Rockville, Maryland, USA.

ORCID-Profile: Jerome Niquet, Claude G Wasterlain

Förderung

  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Steier, H. G., Schultz, C. R., Niquet, J., Nguyen, D. A., Stone, M. F., Biney, A. K., de Araujo Furtado, M., Wasterlain, C. G., & Lumley, L. A. (2025). Perampanel as a second‐line therapy to midazolam reduces soman‐induced status epilepticus and neurodegeneration in rats. Epilepsia Open. https://doi.org/10.1002/epi4.70083

Vancouver

Steier HG, Schultz CR, Niquet J, Nguyen DA, Stone MF, Biney AK, et al. Perampanel as a second‐line therapy to midazolam reduces soman‐induced status epilepticus and neurodegeneration in rats. Epilepsia Open. 2025. doi:10.1002/epi4.70083

BibTeX
@article{Steier2025,
  author = {Steier, Hailey G and Schultz, Caroline R and Niquet, Jerome and Nguyen, Donna A and Stone, Michael F and Biney, Abiel K and de Araujo Furtado, Marcio and Wasterlain, Claude G and Lumley, Lucille A},
  title = {Perampanel as a second‐line therapy to midazolam reduces soman‐induced status epilepticus and neurodegeneration in rats},
  journal = {Epilepsia Open},
  year = {2025},
  doi = {10.1002/epi4.70083}
}
Kostenlos starten →